AbbVie Inc. (LON:0QCV)

Market Cap	243.60B
Revenue (ttm)	44.40B
Net Income (ttm)	3.22B
Shares Out	n/a
EPS (ttm)	1.81
PE Ratio	75.75
Forward PE	14.71
Dividend	4.96 (2.64%)
Ex-Dividend Date	Apr 15, 2025

Volume	3,380
Average Volume	13,362
Open	186.30
Previous Close	188.63
Day's Range	185.28 - 188.40
52-Week Range	158.92 - 218.50
Beta	0.49
RSI	51.95
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD